KIT and chronic myelogenous leukemia, BCR-ABL1 positive: Proportion of CD34+ CD117+ cells in bone marrow:Higher in untreated CML patients (24.7%) than in donors (4.4%). Significant decrease in patients who achieved HRR (11.2%) and CRR (8.9%).HRR: Lower in patients with CD34+ CD117+ cells ≥ 20% before treatment (41.7%) compared to those with < 20%.